By Dr Charlotte Rose Lemech

Book Chapters

Lemech CR; Kristeleit R; Arkenau HT, 2011, 'Novel Oncology Drug Development Strategies in the Era of Personalised Medicine', in Kapetanovic IM (ed.), Drug Discovery and Development - Present and Future

Journal articles

Liu J; Farrow M; Hsing SS; Cosman R; Lemech CR; Teng C; Pal A; Nindra U; Parsonson AO; Park JJW; Rodrigues A; Chan WY; Wei J; Cohen J; Underhill CR; Brungs D; Hui M; Nagrial A; Jain S; Joshua AM, 2026, 'Network-Integrated Platform for Clinical Trial Navigation from the New South Wales Early Phase Clinical Trials Alliance', Clinical Cancer Research an Official Journal of the American Association for Cancer Research, 32, pp. 3991 - 4000, http://dx.doi.org/10.1158/1078-0432.CCR-26-0733

Liu J; Farrow M; Hsing S; Cosman R; Lemech CR; Teng C; Pal A; Nindra U; Parsonson A; Park JJ; Rodrigues A; Chan W; Wei J; Cohen J; Underhill C; Brungs D; Hui M; Nagrial A; Jain S; Joshua AM, 2026, 'Abstract A056: Network-integrated clinical trial navigation with ctDNA profiling improves early-phase trial access: Final results from the PANNA-COTA study', Clinical Cancer Research, 32, pp. a056 - a056, http://dx.doi.org/10.1158/1557-3265.d32026-a056

Tran B; Voskoboynik M; Kim SW; Lemech C; Carcereny E; Rha SY; Ahn MJ; Felip E; Lee KH; Castañón E; Yang JCH; Ascierto PA; Pulla MP; Kondo S; Kuboki Y; Freeman D; Song X; Blando J; Eck S; Song FJ; Tang Z; Kuziora M; Gainer SD; Mitchell P; Asare J; Ayyoub A; Achour I; Subramaniam DS; Im SA, 2026, 'Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody', Clinical Cancer Research, 32, pp. 2850 - 2864, http://dx.doi.org/10.1158/1078-0432.CCR-25-3447

Wang S; Lemech CR; Li N; Wang N; Hu X; Zhang J; Morris MF; Mao W; Jiang H; Zhang F, 2026, 'BL0020, a novel tumor microenvironment (TME)-targeting nano-mediated polypeptide-drug conjugate (NMPDC), in patients with advanced solid tumors: Updated results from the small cell lung cancer (SCLC) subset of a phase 1 study.', Journal of Clinical Oncology, 44, pp. 8095 - 8095, http://dx.doi.org/10.1200/jco.2026.44.16_suppl.8095

Yap TA; Lemech CR; Lau PKH; Coward JIG; Ameratunga M; Luen SJ; Patnaik A; Call JA; Hamilton EP; Wang H; Hunder NNH; Ma S; Smith A; Bansal A; Ayers B; Boyd-Kirkup JD; Ingram P; Lynce F, 2026, 'Phase 1/2 study of CLIO-8221, a HER2-targeted, dual-payload exatecan and ATR inhibitor antibody-drug conjugate (ADC) in patients with advanced HER2-expressing solid tumors.', Journal of Clinical Oncology, 44, pp. tps3162 - tps3162, http://dx.doi.org/10.1200/jco.2026.44.16_suppl.tps3162

Nguyen J; Nindra U; Tang J; Zwieky W; Hong JH; Hong M; Descallar J; Killen A; Cooper A; Wilkinson K; Pal A; Teng C; Roohullah A; Wei J; Ng W; Lemech C; Chua W, 2026, 'Measuring What Matters: RECIST Response Does Not Predict HRQoL in Early-Phase Clinical Trials', Cancers, 18, http://dx.doi.org/10.3390/cancers18081242

Varkaris A; Lipsyc-Sharf M; Barve M; Oprychal M; Giordano A; Hamilton E; Rodon J; Jhaveri K; Kaklamani V; Lemech C; Wu L; Shah RM; Rhee J; Ben Y; Luen SJ, 2026, 'Abstract PS5-07-06: BREAKER-101: a phase 1a/1b open-label study evaluating the safety, tolerability, pharmacokinetics, and efficacy of BBO-10203 in patients with advanced solid tumors', Clinical Cancer Research, 32, http://dx.doi.org/10.1158/1557-3265.sabcs25-ps5-07-06

Liu X; Kuang X; Lemech C; Liu Z; Ding J; Zhou X; Liu X; Wang Y; Liao H; wang W, 2026, 'P-111. Safety, Pharmacokinetics, Pharmacodynamics and Immunogenicity of Siltartoxatug, A First-in-Class Anti-Tetanus Monoclonal Antibody: Results of Two Phase I Trials in Australian and Chinese Healthy Adults', Open Forum Infectious Diseases, 13, http://dx.doi.org/10.1093/ofid/ofaf695.339

Liu X; Liu Z; Kuang X; Wang Y; Liu X; Ding J; Zhou X; Zhou X; Liang Q; Zhang M; Zhao H; Tan Q; Zheng W; Liao H; Lemech C; Wang W, 2026, 'Phase I Evaluation of Siltartoxatug, a First-in-Class Anti-Tetanus Monoclonal Antibody: Safety, Pharmacokinetics and Pharmacodynamics in Healthy Australian and Chinese Populations', Clinical Pharmacology and Therapeutics, http://dx.doi.org/10.1002/cpt.70467

Lemech C; Xu R-H; Ruan D; Parsonson A; Joubert W; Shinde R; Bhave P; Xue J; Gandhi N; Rasco D; Liu H; Gao Y; Xuefeng F; Zhang B; Xing X; Liu S-H; Meng X, 2026, '112P Phase I study of AMT-676, an anti-CDH17 antibody-drug conjugate, in patients with advanced CRC and other GI tumors', Annals of Oncology, 37, pp. s44, http://dx.doi.org/10.1016/j.annonc.2026.05.113

Zhou C; Wang B; Teng C; Yang H; Piha-Paul SA; Richardson G; Malalasekera A; Sun Y; Wang W; Liu J; Shi Y; Zhan X; Lemech C, 2025, 'A phase Ia study of a novel anti-HER2 antibody–drug conjugate GQ1001 in patients with previously treated HER2 positive advanced solid tumors', Journal of Translational Medicine, 23, http://dx.doi.org/10.1186/s12967-024-05985-z

Thoms JAI; Yan F; Hampton HR; Davidson S; Joshi S; Saw J; Sarowar CH; Lim XY; Nunez AC; Kakadia PM; Bhuyan GS; Zou X; Nguyen M; Ghodousi ES; Koch FC; Vafaee F; Thompson IR; Karimi MM; Pickford R; Raftery MJ; Hough S; Buckland G; Bailey M; Ghodke Y; Absar N; Vaughan L; Pasalic L; Fong CY; Kenealy M; Hiwase DK; Stoddart RI; Mohammed S; Lee L; Passam FH; Larsen SR; Spring KJ; Skarratt KK; Rebeiro P; Presgrave P; Stevenson WS; Ling S; Tiley C; Fuller SJ; Roncolato F; Enjeti AK; Hoenemann D; Lemech C; Jolly CJ; Bohlander SK; Curtis DJ; Wong JWH; Unnikrishnan A; Hertzberg M; Olivier J; Polizzotto MN; Pimanda JE, 2025, 'Clinical response to azacitidine in MDS is associated with distinct DNA methylation changes in HSPCs', Nature Communications, 16, http://dx.doi.org/10.1038/s41467-025-59796-x

Nindra U; Tang J; Hong JH; Descallar J; Hong M; Killen A; Dubey P; Attaullah J; Scott G; Cooper A; Wilkinson K; Pal A; Teng C; Roohullah A; Wei J; Ng W; Lemech C; Chua W, 2025, 'Prospective assessment of health-related quality of life in early phase oncology clinical trials: PEARLER', Jnci Cancer Spectrum, 9, http://dx.doi.org/10.1093/jncics/pkaf108

Nindra U; Tang J; Hong JH; Descallar J; Hong M; Killen A; Dubey P; Attaullah J; Scott G; Cooper A; Wilkinson K; Pal A; Teng C; Roohullah A; Wei J; Ng W; Lemech C; Chua W, 2025, 'Assessing Patient-Reported Financial, Social, and Time Toxicity in Early-Phase Cancer Clinical Trials in Australia Through a Prospective Multicenter Nonrandomized Cohort Study', JCO Oncology Practice, 3, pp. 1 - 1, http://dx.doi.org/10.1200/OP-25-00412

Kang E; Kim D; Hwang S; Lemech C; Wharton J; Lee Y; Yoo HW; Lee BH, 2025, 'A Randomized, Double-Blind, 2-Treatment, 2-Period, Crossover Phase 1 Study to Compare the Pharmacokinetics, Safety and Tolerability of 60 IU/Kg of Abcertin and Cerezyme in Healthy Volunteers Following a Single Intravenous Administration', Molecular Genetics and Genomic Medicine, 13, http://dx.doi.org/10.1002/mgg3.70111

Lemech CR; Cosman R; Humphries TG; Kichenadasse G; Richardson GE; Nagrial A; Teng C; Liu J; Joshua AM; Cohen H; Mo J; Harvey K; Zhang H; Ling Z; King N; Barnett M; Cioffi M; Maurer MA; Getts D; Swarbrick A, 2025, 'First-in-human mRNA CAR therapy: Correlative biomarker analysis from the MT-302 phase 1 study targeting TROP2 in patients with advanced epithelial tumors.', Journal of Clinical Oncology, 43, pp. 2591 - 2591, http://dx.doi.org/10.1200/JCO.2025.43.16_suppl.2591

Atkinson VG; Brenner W; Brown JT; Cabezón-Gutiérrez L; Gajate P; Kim ST; Lee J; Lemech C; Margolin KA; Moreno I; Moreno V; Oh D-Y; Oliva IG; Park JJ; Shue H; Twardowski P; Winer I; Chisamore MJ; Prawira A; Merchant F; Coello M; To MD; Merchant R; Yavari A; Ascierto PA, 2025, 'Abstract CT047: Interim results from the phase 1/2 ABILITY-1 study of a long-acting ‘beta-enhanced not-alpha’ IL-2 superkine in patients with advanced solid tumors', Cancer Research, 85, pp. ct047 - ct047, http://dx.doi.org/10.1158/1538-7445.am2025-ct047

Lu S; Lemech C; Abed A; Powderly J; Liu SV; Li Z; Jiang L; Gu W; Liu Q; Fang L; Qiu Y; Shi R; Liu Y, 2025, 'Abstract CT121: A phase 1/2a, multicenter, open-label, first in human study of a bispecific ADC targeting B7H3 and PDL1 (DB-1419) in advanced or metastatic solid tumors', Cancer Research, 85, pp. ct121 - ct121, http://dx.doi.org/10.1158/1538-7445.am2025-ct121

Tran B; Frentzas S; Lemech CR; Millward M; Day D; Desai J; Latifi A; Wabnitz P; Kearney P; Galkin AV, 2025, 'Abstract 5850: AXA-042, a systemically administered TLR2/6 agonist, demonstrates innate immune engagement and Th1 polarization in patients with advanced solid tumors', Cancer Research, 85, pp. 5850 - 5850, http://dx.doi.org/10.1158/1538-7445.am2025-5850

Nindra U; Tang J; Hong JH; Hong M; Teng C; Wei J; Killen A; Cooper A; Wilkinson K; Ng W; Lemech C; Chua W; Pal A, 2025, 'Evaluating patient diversity in early phase clinical trials in Australia through a prospective multicenter nonrandomized cohort study', Jnci Cancer Spectrum, 9, http://dx.doi.org/10.1093/jncics/pkaf035

Song Y; Xie L; Zhang Y; Wu H; Pratyush G; Huang H; Cen H; Guo Y; Fan L; Li Y; Li M; Sun X; Liang X; Lemech C; Wang J; Zhu X; Li F; Dai H; Shi Q; Yang JJ, 2025, '1316eTiP A phase Ib trial of CS5001 (ROR1-ADC) as a single agent and in combination with systemic therapies in patients with advanced solid tumours and lymphomas', Annals of Oncology, 36, pp. s822 - s823, http://dx.doi.org/10.1016/j.annonc.2025.08.1947

Wang S; Lemech C; Li N; Wang N; Hu X; Zhang J; Morris M; Mao W; Jiang H; Zhang F, 2025, '2780P BL0020, a novel targeting tumor microenvironment (TME) nano-mediated polypeptide-drug conjugate (NMPDC), in patients with advanced solid tumors: Results from a phase I study', Annals of Oncology, 36, pp. s1479, http://dx.doi.org/10.1016/j.annonc.2025.08.3391

Yap TA; Lemech C; Voskoboynik M; Millward M; Hafez M; Tam L; Subbiah V; Call JA; Zhou Y; Terry K; O'Hayer K; Lorusso PM, 2025, '923MO First results from a phase I trial of SNV1521, a next generation, CNS-penetrant, PARP1-selective inhibitor in patients (pts) with molecularly selected advanced solid tumors', Annals of Oncology, 36, pp. s603 - s604, http://dx.doi.org/10.1016/j.annonc.2025.08.1492

Liu JJ; Farrow M; Hsing S; Cosman R; Lemech C; Teng C; Pal A; Nindra U; Parsonson A; Park JJW; Underhill CR; Hui MN; Nagrial A; Jain SS; Joshua AM, 2025, '991P PANNA-COTA (Practical assessment of NECTA network assistance in cancer outpatient trials access): A prospective investigator-led trial using ctDNA to inform early phase trial matching', Annals of Oncology, 36, pp. s649, http://dx.doi.org/10.1016/j.annonc.2025.08.1560

Lemech CR; Joubert WL; Parsonson AO; Xu R-H; Shinde R; Bhave P; Xue J; Huang Y; Meng X; Liu S-H, 2025, 'A phase 1, first-in-human study of AMT-676, an anti-CDH17 antibody-drug conjugate, in patients with advanced gastrointestinal tumors.', Journal of Clinical Oncology, 43, pp. tps3161 - tps3161, http://dx.doi.org/10.1200/jco.2025.43.16_suppl.tps3161

Nindra U; Tang J; Hong JH; Descallar J; Hong M; Killen AJ; Cooper AJ; Wilkinson KJ; Pal A; Teng C; Roohullah A; Wei J; Ng WL; Lemech CR; Chua W, 2025, 'Financial, social and time toxicity in early-phase cancer clinical trials: The PEARLER study.', Journal of Clinical Oncology, 43, pp. 11119 - 11119, http://dx.doi.org/10.1200/jco.2025.43.16_suppl.11119

Lemech CR; Sun Y; Nagrial A; Wu X; Morris MF; Ning F; Yang J; Pan Y; Cai J; Lu P; Zhang T; Qiu F; Hu C; Zhang M; Liu Z; Han G; Nie J; Teng C; Zhou H; Day D, 2025, 'IBI354 (anti-HER2 antibody-drug conjugate [ADC]) in patients (pts) with HER2-positive breast cancer (BC) and other solid tumors: Updates from a phase 1 study.', Journal of Clinical Oncology, 43, pp. 1029 - 1029, http://dx.doi.org/10.1200/jco.2025.43.16_suppl.1029

Nguyen JTT; Nindra U; Tang J; Hong JH; Zwieky W; Hong M; Killen A; Wilkinson K; Pal A; Teng C; Roohullah A; Wei J; Ng WL; Lemech C; Chua W, 2025, 'Measuring what matters: RECIST response does not predict HRQoL in early-phase trials', ANNALS OF ONCOLOGY, 36, http://dx.doi.org/10.1016/j.annonc.2025.10.1003

Nindra U; Hong JH; Tang J; Descallar J; Hong M; Killen AJ; Cooper AJ; Wilkinson KJ; Pal A; Teng C; Roohullah A; Wei J; Ng WL; Lemech CR; Chua W, 2025, 'Prospective assessment of health-related quality of life in early phase clinical trials.', Journal of Clinical Oncology, 43, pp. 11118 - 11118, http://dx.doi.org/10.1200/jco.2025.43.16_suppl.11118

Song Y; Zhang J; Zhou K; Zhang L; Barve M; Lemech C; Li W; Cherng H-JJ; Huang H; Xie L; Zuniga R; Zhou C; Shen L; Yang S; Bishnoi S; Zhang Y; Wang J; Zhu X; Li F; Yang J, 2024, 'Safety and Efficacy in Patients with Advanced Lymphomas from a Global Phase 1a/1b, First-in-Human Study of CS5001, a Novel Anti-ROR1 ADC', Blood, 144, pp. 1739 - 1739, http://dx.doi.org/10.1182/blood-2024-192979

Hayes AG; Jonker B; Teng C; Lemech C; Killen AJ; Sim HW; McCormack AI, 2024, 'Approach to the Patient: New Era Emerges for Craniopharyngioma Management', Journal of Clinical Endocrinology and Metabolism, 109, pp. 2986 - 2996, http://dx.doi.org/10.1210/clinem/dgae503

Mercuri FA; White S; McQuilten HA; Lemech C; Mynhardt S; Hari R; Zhang P; Kruger N; McLachlan G; Miller BE; West NP; Tal-Singer R; Demaison C, 2024, 'Evaluation of intranasal TLR2/6 agonist INNA-051: safety, tolerability and proof of pharmacology', ERJ Open Research, 10, pp. 00199 - 02024, http://dx.doi.org/10.1183/23120541.00199-2024

Armstrong AJ; Geva R; Chung HC; Lemech C; Miller WH; Hansen AR; Lee JS; Tsai F; Solomon BJ; Kim TM; Rolfo C; Giranda V; Ren Y; Liu F; Kandala B; Freshwater T; Wang JS, 2024, 'Correction to: CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial(Investigational New Drugs, (2024), 42, (145-159), 10.1007/s10637-023-01410-2)', Investigational New Drugs, 42, pp. 340 - 341, http://dx.doi.org/10.1007/s10637-024-01444-0

Wahlroos S; Teng C; Tran B; Voskoboynik M; Gan HK; Spencer A; Kudva A; Song M; Lynch K; Yu Z; Desai J; Lemech CR, 2024, 'Results of a first-in-human, dose-escalation phase 1 study of the ERK1/2 inhibitor ATG-017 in patients with advanced solid tumors.', Journal of Clinical Oncology, 42, pp. e15114 - e15114, http://dx.doi.org/10.1200/jco.2024.42.16_suppl.e15114

Frentzas S; Mislang ARA; Lemech C; Nagrial A; Underhill C; Wang W; Wang ZM; Li B; Xia Y; Coward JIG, 2024, 'Phase 1a dose escalation study of ivonescimab (AK112/SMT112), an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors', Journal for Immunotherapy of Cancer, 12, http://dx.doi.org/10.1136/jitc-2023-008037

Dorff T; Horvath LG; Autio K; Bernard-Tessier A; Rettig MB; Machiels JP; Bilen MA; Lolkema MP; Adra N; Rottey S; Greil R; Matsubara N; Tan DSW; Wong A; Uemura H; Lemech C; Meran J; Yu Y; Minocha M; McComb M; Penny HL; Gupta V; Hu X; Jurida G; Kouros-Mehr H; Janat-Amsbury MM; Eggert T; Tran B, 2024, 'A Phase I Study of Acapatamab, a Half-life Extended, PSMA-Targeting Bispecific T-cell Engager for Metastatic Castration-Resistant Prostate Cancer', Clinical Cancer Research, 30, pp. 1488 - 1500, http://dx.doi.org/10.1158/1078-0432.CCR-23-2978

Cheng Y; Lisberg A; Lemech C; Abed A; Chaudhry A; Schmidt A; Lu X; Zhu Z; Gu W; Qiu Y; Shi R; Zhang B, 2024, 'Abstract CT165: A phase 1/2a, multicenter, open-label, first-in-human study to assess the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of DB-1311 (a B7-H3-targeting ADC) in patients with advanced/metastatic solid tumors', Cancer Research, 84, pp. ct165 - ct165, http://dx.doi.org/10.1158/1538-7445.am2024-ct165

Atkinson VG; Antras JF; Bedard P; Brenner W; Brown J; Lemech CR; Lloyd P; Margolin K; Mathew M; Park JJ; Thomas S; Twardowski P; Gardner H; Prawira A; Coello M; Ebrahimimizadeh W; To MD; Merchant R; Karanam SM; Yavari A; Siu LL; Tawbi HA; Ascierto PA, 2024, 'Abstract CT259: Results from monotherapy dose escalation of MDNA11, a long-acting IL-2 superkine, in a phase 1/2 trial show evidence of single-agent activity in advanced solid tumors', Cancer Research, 84, pp. ct259 - ct259, http://dx.doi.org/10.1158/1538-7445.am2024-ct259

Armstrong AJ; Geva R; Chung HC; Lemech C; Miller WH; Hansen AR; Lee JS; Tsai F; Solomon BJ; Kim TM; Rolfo C; Giranda V; Ren Y; Liu F; Kandala B; Freshwater T; Wang JS, 2024, 'CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial', Investigational New Drugs, 42, pp. 145 - 159, http://dx.doi.org/10.1007/s10637-023-01410-2

Tran B; Voskoboynik M; Bendell J; Gutierrez M; Lemech C; Day D; Frentzas S; Garrido-Laguna I; Standifer N; Wang F; Ferte C; Wang Y; Das M; Carneiro BA, 2024, 'A phase 1 study of the CD40 agonist MEDI5083 in combination with durvalumab in patients with advanced solid tumors', Immunotherapy, 16, pp. 759 - 774, http://dx.doi.org/10.1080/1750743X.2024.2359359

Lemech CR; Zuniga R; Barve MA; Song Y; Zhang J; Zhou K; Zhang L; Shen L; Bishnoi S; Cherng HJJ; Zhou C; Li W; Wang J; Zhu X; Zhu D; Li F; Shen Z; Yang J, 2024, 'A phase 1a/b, multi-regional, first-in-human study of CS5001, a novel anti-ROR1 ADC, in patients with advanced solid tumors and lymphomas.', Journal of Clinical Oncology, 42, pp. 3023 - 3023, http://dx.doi.org/10.1200/JCO.2024.42.16_suppl.3023

Thoms J; Hampton H; Yan F; Davidson S; Joshi S; Sarowar C; Lim XY; Nunez A; Kakadia P; Saw J; Bhuyan GS; Zou X; Ghodousi E; Jolly C; Koch F; Vafaee F; Pickford R; Raftery M; Hough S; Buckland G; Bailey M; Ghodke Y; Absar N; Vaughan L; Pasalic L; Fong C; Kenealy M; Hiwase D; Stoddart R; Mohammed S; Lee L; Passam F; Spring K; Skarratt K; Rebeiro P; Larsen S; Presgrave P; Stevenson W; Ling S; Tiley C; Fuller S; Roncolato F; Enjeti A; Hoenemann D; Lemech C; Curtis D; Bohlander S; Olivier J; Hertzberg M; Unnikrishnan A; Polizotto M; Pimanda J, 2024, '3178 – LONGITUDINAL DRUG INCORPORATION, CLONAL COMPOSITION, AND DNA METHYLATION DYNAMICS IN MDS/CMML PATIENTS TREATED WITH AZA', Experimental Hematology, 137, pp. 104498, http://dx.doi.org/10.1016/j.exphem.2024.104498

Lemech C; Sun Y; Nagrial A; Wu X; Morris M; Ning F; Yang J; Pan Y; Cai J; Lu P; Zhang T; Qiu F; Hu C; Zhang M; Liu Z; Han G; Nie J; Teng C; Zhou H; Day D, 2024, '345MO IBI354 (anti-HER2 antibody-drug conjugate [ADC]) in patients (pts) with advanced solid tumors and breast cancer (BC): Results from a phase I study', Annals of Oncology, 35, pp. s360, http://dx.doi.org/10.1016/j.annonc.2024.08.293

Gong J; Lemech C; Day D; Shan J; Morris M; Nagrial A; Chen M; Huang X; Zong H; Wang N; Yang Y; Yi T; Li W; Zhuang Z; Li Z; Liu Z; Luo Y; Zhang Y; Zhou H; Shen L, 2024, '576P Safety and efficacy of IBI354 (anti-HER2 ADC) in patients (pts) with advanced gastrointestinal (GI) cancers: Results from a phase I study', Annals of Oncology, 35, pp. s467 - s468, http://dx.doi.org/10.1016/j.annonc.2024.08.645

Cheng Y; Wu L; Parsonson A; Amin H; Shi J; Lemech C; Sun Y; Schmidt A; Lv D; Li M; Zheng T; Chaudhry A; Gandhi C; Wang Q; Motino DAM; Abed A; Tibes R; Lu X; Gu V; Lisberg AE, 2024, '57O A phase I/II multicenter, first-in-human study of DB-1311/BNT324 (a novel B7H3 ADC) in patients with advanced solid tumors', Annals of Oncology, 35, pp. s1426, http://dx.doi.org/10.1016/j.annonc.2024.10.078

Lemech C; Kichenadasse G; Teng C; Nagrial A; Richardson G; Humphries TG; Killen AJ; Joshua A; Liu JJ; Churchill M; Barnett M; Cioffi M; Cosman R, 2024, '676TiP MYE Symphony: A first-in-human study to investigate the safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of the in vivo mRNA CAR therapy, MT-302, targeting TROP2 in adults with advanced epithelial tumors', Annals of Oncology, 35, pp. s528, http://dx.doi.org/10.1016/j.annonc.2024.08.742

Lemech C; Luke JJ; Falchook GS; Mckean M; Kichenadasse G; Teng C; Vandross AL; Salkeni MA; Atkinson VG; Liu JJ; Kennedy AM; Clark J; Ryan M; Schmidt-Kittler O; Steinhubel D; Wages D; Komarnitsky P; Puzanov I, 2024, '678TiP A phase I, first-in-human, dose escalation and expansion study of oral pan-RAF/MEK molecular glue NST-628 in subjects with solid tumors harboring RAS-MAPK pathway alterations', Annals of Oncology, 35, pp. s528 - s529, http://dx.doi.org/10.1016/j.annonc.2024.08.744

Lee S-H; Han J-Y; Lee KH; Lee G-W; Lemech C; Millward M; Roohullah A; Le X; Park K; Choi JY; Kim NY; Im S; Rajasekaran N; Park KE; Lee S; Moon H; Hwang S; Shin Y; Lee DH, 2023, 'Abstract B042: Efficacy and safety outcomes of ABN401 in NSCLC patients with MET Exon 14 Skipping: A clinically relevant subgroup analysis', Molecular Cancer Therapeutics, 22, pp. b042 - b042, http://dx.doi.org/10.1158/1535-7163.targ-23-b042

Day D; Park JJ; Coward J; Markman B; Lemech C; Kuo JC; Prawira A; Brown MP; Bishnoi S; Kotasek D; Strother RM; Cosman R; Su R; Ma Y; Yue Z; Hu HH; Wu R; Li P; Tse AN, 2023, 'A first-in-human phase 1 study of nofazinlimab, an anti-PD-1 antibody, in advanced solid tumors and in combination with regorafenib in metastatic colorectal cancer', British Journal of Cancer, 129, pp. 1608 - 1618, http://dx.doi.org/10.1038/s41416-023-02431-7

Back to profile page